clinical trial · NCT06370728
A Drug-Drug Interaction (DDI) Study of Orforglipron With Carbamazepine in Healthy Participants
Eli Lilly and Company·phase1·completed·n = 30
HealthyOrforglipronCarbamazepine
brief summary
The main purpose of this study is to assess the effect of carbamazepine on the amount of orforglipron in the bloodstream and how long it takes the body to get rid of orforglipron when given orally in healthy study participants. The safety and tolerability of orforglipron and carbamazepine when given separately or together will also be evaluated. The study may last up to approximately 77 days for each participant.
started
May 6, 2024
primary completion
Jul 23, 2024
completion
Jul 23, 2024
last updated
Jul 17, 2026
official title
A Drug-Drug Interaction Study to Assess the Effect of Carbamazepine on the Pharmacokinetics of Orforglipron in Healthy Participants
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol